logo

Active Pharmaceutical Ingredients Market, By Type (Generic, Innovative), Manufacturer (Merchant, Captive), Synthesis (Synthetic, Biotech), Product (Hormone, mAb, Biosimilar) Drug (OTC, Rx), Therapy, opportunities and forecast 2020-2027

  • DLR2103
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

The API Market is one of the growing market in the pharmaceutical industry. Patent expiration of some of the major pharmaceutical and continuous need for generic drugs are some of the major factors driving the growth of the market.

Based on type, the API market is divided as synthetic API and Biotech API. Synthetic segment is further segmented into innovative API and Generic APis. Synthetic API due to increasing demand from the pharmaceutical industry accounts for the major market share in 2011. Innovative APIs commands the major market share, while the increasing demand for generic production is expected to grow at a fastest rate during the forecast period.

The pharmaceutical API developing industry undergoes period of rapid change because of multiple factors. For instance, patent expiry in top selling pharmaceuticals, the ever changing nature of the drugs being manufactured and the surge in API manufacturing from the emerging regions.

Segment Overview

In a periodic study of majority drugs for patients, API marketing has deemed to be a good factor in driving growth of Market. Demand for Research and innovation has led to production of drugs with Highly Potent Active Pharmaceutical Ingredient (HPAPI) and other biologically similar products creating opportunities in the field of API market.

On the basis of route of synthesis, the Global API market is divided into two broad categories: synthetic chemicals API and biopharmaceuticals API. Innovative synthetic chemical API and generic synthetic chemical API form primary segments of the synthetic chemical API market. In 2011 the innovative segment accounts for a higher share of almost 60% in the market. However, their share is expected to decline to about 50% in 2016,

Regional Overview

Being most exceptional part of every formulated end product, Active Pharmaceutical Ingredient (API) has become an imperative section of entire pharmaceutical industry. The increasing occurrence of chronic diseases, rising importance of the generics, and growing uptake of biopharmaceuticals are few of the major factors that are driving the growth of global APIs market. On other hand, the unfavourable price control policies for the drugs across various countries and increasing penetration of counterfeit drugs are anticipated to restrain growth of the market in the coming years.

Competitor overview

Major players of this market are Teva Pharmaceuticals Ltd. (Israel), Sandoz (Switzerland) (generic subsidiary of Novartis), Lonza Group-AG (Switzerland), DSM (Netherland), Dr. Reddy’s Lab Ltd. (India) and Boehringer Ingelheim GmbH (Germany). Generic sales are expanding as consequence of expansion in emerging pharmaceutical markets such as APAC, LatAm and Eastern Europe.

Pfizer is one of leading players in global API industry. The position of the company is attributed to its thorough product portfolio. The company has strong brand image that gives it competitive edge over the other players. Furthermore, in order to continue to be competitive and strengthen the market position, company primarily emphases on adopting both organic and inorganic growth strategies such as agreements, collaborations, partnerships, product approvals, and acquisitions.

Key Players
  1. Teva Pharmaceuticals Ltd.
  2. Sandoz
  3. Lonza Group-AG
  4. DSM
  5. Dr. Reddy’s Lab Ltd.
  6. Boehringer Ingelheim GmbH

Market Segmentation

By Type
  • Generic
  • Innovative
By Synthesis
  • Synthetic
  • Biotech
By Product
  • Hormone
  • mAb
  • Biosimilar
By Drug
  • OTC
  • Rx
By Manufacturer
  • Merchant
  • Captive
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 16

    2 Market Introduction 19

    • 2.1 Scope of Study 20
    • 2.2 Research Objective 20
    • 2.3 List of Assumptions 20
    • 2.4 Market Structure 21

    3 Research Methodology 22

    • 3.1 Research Process 23
    • 3.2 Primary Research 24
    • 3.3 Secondary Research 25
    • 3.4 Market Size Estimation 26
    • 3.5 Forecast Model 26

    4 Market Dynamics 27

    • 4.1 Introduction 28
      • 4.1.1 Drivers 28
        • 4.1.1.1 Increasing occurrences of chronic diseases 28
        • 4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA) 29
        • 4.1.1.3 Rising acceptance and uptake of biopharmaceuticals 29
        • 4.1.1.4 Growing importance of generics 30
      • 4.1.2 Restraints 30
        • 4.1.2.1 Stringent regulatory policies 30
        • 4.1.2.2 Adverse drug price control policies across numerous countries 30
      • 4.1.3 Opportunities 31
        • 4.1.3.1 Emerging biosimilar market 31
  • 4.2 Increasing scope for high-potency active pharmaceutical ingredients 31
  • 4.3 Macroeconomic indicators 31

    • 5 Market Factor Analysis 32

    • 5.1 Porter’s Five Forces Model 33
      • 5.1.1 Bargaining Power of Suppliers 33
      • 5.1.2 Bargaining Power of Buyers 34
      • 5.1.3 Threat of New Entrants 34
      • 5.1.4 Threat of Substitutes 34
      • 5.1.5 Intensity of Rivalry 34
    • 5.2 Value Chain Analysis 35
      • 5.2.1 Research &Development 35
      • 5.2.2 Manufacturing 35
      • 5.2.3 Distribution 35
      • 5.2.4 Marketing & Sales 36
      • 5.2.5 Post-Sales Monitoring 36
    • 5.3 Demand & Supply: Gap Analysis 36
    • 5.4 Pricing Analysis 36

    6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process 37

    • 6.1 Introduction 38
      • 6.1.1 Captive Manufacturing 40
      • 6.1.2 Contract Manufacturing 40

    7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis 41

    • 7.1 Introduction 42
    • 7.2 Synthetic 43
    • 7.3 Biotech 44
      • 7.3.1 Monoclonal Antibodies 44
      • 7.3.2 Recombinant proteins 44
      • 7.3.3 Vaccines 45
      • 7.3.4 Others 45

    8 Global Active Pharmaceutical Ingredients Market, by API Formulation 46

    • 8.1 Introduction 47
    • 8.2 Generic API 48
    • 8.3 Branded/ Innovative API 49

    9 Global Active Pharmaceutical Ingredients Market, by Application 50

    • 9.1 Introduction 51
    • 9.2 Cardiovascular Disease 54
    • 9.3 Oncology 54
    • 9.4 Neurological Disorders 54
    • 9.5 Orthopedic Disorders 55
    • 9.6 Respiratory 55
    • 9.7 Gastrointestinal Disorders 55
    • 9.8 Urology 56
    • 9.9 Others 56

    10 Global Active Pharmaceutical Ingredients Market, by Molecule 57

    • 10.1 Introduction 58
    • 10.2 Molecule 58
    • 10.3 Large Molecule 59
    • 10.4 Small Molecule 59

    11 Global Active Pharmaceutical Ingredients Market, by Region 60

    • 11.1 Introduction 61
    • 11.2 Americas 62
      • 11.2.1 North America 65
        • 11.2.1.1 U.S. 67
        • 11.2.1.2 Canada 69
      • 11.2.2 South America 71
    • 11.3 Europe 73
      • 11.3.1 Western Europe 76
        • 11.3.1.1 Germany 78
        • 11.3.1.2 France 80
        • 11.3.1.3 U.K. 82
        • 11.3.1.4 Italy 84
        • 11.3.1.5 Spain 86
        • 11.3.1.6 Rest of Western Europe 88
      • 11.3.2 Eastern Europe 90
    • 11.4 Asia Pacific 92
      • 11.4.1 Asia Pacific 93
      • 11.4.2 Japan 95
      • 11.4.3 China 97
      • 11.4.4 India 99
      • 11.4.5 Australia 101
      • 11.4.6 Republic of Korea 103
      • 11.4.7 Rest of Asia Pacific 105
    • 11.5 The Middle East & Africa 107
      • 11.5.1 Middle East and Africa 108
      • 11.5.2 Middle East 110
        • 11.5.2.1 Saudi Arabia 111
      • 11.5.3 Africa 114
        • 11.5.3.1 North Africa 116

    12 Competitive Landscape 118

    • 12.1 Company Market Share Analysis 119
      • 12.1.1 Introduction 119
    • 12.2 Merger and Acquisition 119
    • 12.3 Major Strategies adopted by market players 120
    • 12.4 Competitive Landscape 121
      • 12.4.1 Introduction 121
      • 12.4.2 Strategic Partnership 121
    • 12.5 Key Developments 122
    • 12.6 Potential Molecules 126

    13 Company Profiles 127

    • 13.1 Sanofi 128
      • 13.1.1 Company Overview 128
      • 13.1.2 Financial Overview 128
      • 13.1.3 Products Offering 129
      • 13.1.4 Key Developments 130
      • 13.1.5 SWOT Analysis 131
      • 13.1.6 Key Strategy 131
    • 13.2 Bayer AG 132
      • 13.2.1 Company Overview 132
      • 13.2.2 Financial Overview 132
      • 13.2.3 Products Offering 133
      • 13.2.4 Key Developments 134
      • 13.2.5 SWOT Analysis 135
      • 13.2.6 Key Strategy 135
    • 13.3 Pfizer Inc. 136
      • 13.3.1 Company Overview 136
      • 13.3.2 Financial Overview 136
      • 13.3.3 Products Offering 137
      • 13.3.4 Key Developments 138
      • 13.3.5 SWOT Analysis 139
      • 13.3.6 Key Strategy 139
    • 13.4 F. Hoffmann-La Roche AG 140
      • 13.4.1 Company Overview 140
      • 13.4.2 Financial Overview 140
      • 13.4.3 Products Offering 141
      • 13.4.4 Key Developments 142
      • 13.4.5 SWOT Analysis 142
      • 13.4.6 Key Strategy 142
    • 13.5 Abbott Laboratories 143
      • 13.5.1 Company Overview 143
      • 13.5.2 Financial Overview 143
      • 13.5.3 Products Offering 144
      • 13.5.4 Key Developments 144
      • 13.5.5 SWOT Analysis 145
      • 13.5.6 Key Strategy 145
    • 13.6 Merck & Co., Inc. 146
      • 13.6.1 Company Overview 146
      • 13.6.2 Financial Overview 146
      • 13.6.3 Products Offering 147
      • 13.6.4 Key Developments 148
      • 13.6.5 SWOT Analysis 149
      • 13.6.6 Key Strategy 149
    • 13.7 Boehringer Ingelheim GmbH 150
      • 13.7.1 Company Overview 150
      • 13.7.2 Financial Overview 150
      • 13.7.3 Products Offering 151
      • 13.7.4 Key Developments 152
      • 13.7.5 SWOT Analysis 152
      • 13.7.6 Key Strategy 152
    • 13.8 Glaxosmithkline Plc (GSK) 153
      • 13.8.1 Company Overview 153
      • 13.8.2 Financial Overview 153
      • 13.8.3 Products Offering 154
      • 13.8.4 Key Developments 154
      • 13.8.5 SWOT Analysis 155
      • 13.8.6 Key Strategy 155
    • 13.9 Novartis AG 156
      • 13.9.1 Company Overview 156
      • 13.9.2 Financial Overview 156
      • 13.9.3 Products Offering 157
      • 13.9.4 Key Developments 158
      • 13.9.5 SWOT Analysis 159
      • 13.9.6 Key Strategy 159
    • 13.10 Eli Lilly and Company 160
      • 13.10.1 Company Overview 160
      • 13.10.2 Financial Overview 160
      • 13.10.3 Products Offering 161
      • 13.10.4 Key Developments 161
      • 13.10.5 SWOT Analysis 161
      • 13.10.6 Key Strategy 162
    • 13.11 Teva Pharmaceutical Industries Ltd 163
      • 13.11.1 Company Overview 163
      • 13.11.2 Financial Overview 163
      • 13.11.3 Products Offering 164
      • 13.11.4 Key Developments 164
      • 13.11.5 SWOT Analysis 165
      • 13.11.6 Key Strategy 165

    14 Conclusion 166

    • 14.1 Key Findings 167
      • 14.1.1 CEO’s Viewpoint 167
      • 14.1.2 Unmet Needs 167
      • 14.1.3 Key Companies to Watch 167
      • 14.1.4 Prediction 167

    15 Appendix 168

    • 15.1 Discussion Blue Print 169
      • 15.1.1 References 171

    Report You Might be Interested

    • USD
    • GBP
    • EURO
    • INR
    Credit card Logo

    Keywords